<code id='8D1EF352B2'></code><style id='8D1EF352B2'></style>

<acronym id='8D1EF352B2'></acronym>

<center id='8D1EF352B2'><center id='8D1EF352B2'><tfoot id='8D1EF352B2'></tfoot></center><abbr id='8D1EF352B2'><dir id='8D1EF352B2'><tfoot id='8D1EF352B2'></tfoot><noframes id='8D1EF352B2'>

<optgroup id='8D1EF352B2'><strike id='8D1EF352B2'><sup id='8D1EF352B2'></sup></strike><code id='8D1EF352B2'></code></optgroup>

<b id='8D1EF352B2'><label id='8D1EF352B2'><select id='8D1EF352B2'><dt id='8D1EF352B2'><span id='8D1EF352B2'></span></dt></select></label></b><u id='8D1EF352B2'></u>

~~<i id='8D1EF352B2'><strike id='8D1EF352B2'><tt id='8D1EF352B2'><pre id='8D1EF352B2'></pre></tt></strike></i>~~

Home» focus» focus

focus

focus

author：focus 2025-10-02 15:37:26 Page View：76

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

advertisement

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA drug safety: Singulair case shows systemic surveillance flaws
Next article： 23andMe had bad news about my health. I wish a person had delivered it

Wikipedia

After affirmative action ruling, medical educators look to 'holistic review'

After affirmative action ruling, medical educators look to 'holistic review'

AnnaMoneymaker/GettyImagesAfterhavingadaytoreadthroughtheSupremeCourt’sdecisiononaffirmativeaction,s

Readout LOUD podcast: Vertex data, Aduhelm, & Woodcock retires

Whatmakesablockbuster?CanbiotechlearnfromAduhelm?Andhowdoyoureplaceasingularregulator?Wecoverallthat

After affirmative action ruling, medical educators look to 'holistic review'

After affirmative action ruling, medical educators look to 'holistic review'

AnnaMoneymaker/GettyImagesAfterhavingadaytoreadthroughtheSupremeCourt’sdecisiononaffirmativeaction,s

Doctors are clamoring for more clarity on Paxlovid prescribing

ApatientwithpillsofPaxlovid.SixmonthsaftertheemergencyuseauthorizationofPaxlovidforhigh-riskCovidpat

read more